Sign Out
Pregnancy: There are no adequate data on the use of voriconazole in pregnant women available.
Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). The potential risk for humans is unknown.
Voriconazole Kabi must not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.
Women of child-bearing potential: Women of child-bearing potential must always use effective contraception during treatment.
Breast-feeding: The excretion of voriconazole into breast milk has not been investigated. Breast-feeding must be stopped on initiation of treatment with Voriconazole Kabi.
Fertility: In an animal study, no impairment of fertility was demonstrated in male and female rats (see Pharmacology: Toxicology: Preclinical safety data under Actions).
